Q4 2023 Vaxart Inc Earnings Call
Vaxart discussed its 2023 achievements, including progress in oral vaccine development for norovirus and COVID-19, highlighted by a $9.27M BARDA contract for a Phase IIb COVID-19 trial. The company emphasized the potential of its oral pill vaccines to offer advantages over injectables, such as ease of administration and mucosal immunity. Vaxart also announced the appointment of a new CEO, Steve Lo, and shared updates on financial results and future clinical trial plans.
Reference News
Vaxart discussed its 2023 achievements, including progress in oral vaccine development for norovirus and COVID-19, highlighted by a $9.27M BARDA contract for a Phase IIb COVID-19 trial. The company emphasized the potential of its oral pill vaccines to offer advantages over injectables, such as ease of administration and mucosal immunity. Vaxart also announced the appointment of a new CEO, Steve Lo, and shared updates on financial results and future clinical trial plans.